Verzenio® (abemaciclib) increases OS in HR+, HER2-, high-risk early breast cancer with two years of therapy September 3, 2025
FDA INTERACT meeting completed in preparation to advance TBC-1 toward IND-enabling studies September 3, 2025
Type A meeting scheduled with FDA scheduled to discuss CRL for BLA for RP1 + nivolumab combo in advanced melanoma September 3, 2025
TT125-802 received two Fast Track designations in patients with NSCLC with either EGFR Ex19del or Ex21 L858R substitution mutation or KRAS-G12C mutation September 3, 2025
NDA Submission of Gedatolisib in PIK3CA WT Cohort in HR+/HER2- Advanced Breast Cancer to be Initiated Under FDA’s RTOR Program September 3, 2025
FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer September 3, 2025
ENHERTU® Approved in Japan for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy September 3, 2025
Hong Kong Department of Health approves TIVDAK (tisotumab vedotin-tftv) in Hong Kong for patients with recurrent or metastatic cervical cancer September 3, 2025
DATROWAY® Approved in China for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer September 3, 2025
FDA approved CAMCEVI ETM long-acting injectable formulation for advanced prostate cancer September 3, 2025
